Скачать или смотреть Why Is Picking Biotech Stocks SO HARD? Here's How VCs Do It 🧬

Why is picking biotech stocks SO DAMN HARD?

90% fail. Clinical trials collapse overnight. One bad headline and your portfolio is down 50%.

So how do the TOP biotech VCs — ARCH, Third Rock, Atlas Venture — exposed to make BILLIONS while retail investors lose money?

I studied their playbook. Here's the 5-point checklist they use.

🔬 THE VC CHECKLIST:
1️⃣ Top-tier VC backed pre-IPO
2️⃣ Same VC invested across multiple rounds
3️⃣ VC participated in post-IPO offerings
4️⃣ Trusted CEO with track record
5️⃣ Platform validated by real data

📌 4 STOCKS THAT PASS EVERY TEST:

1️⃣ KYMR (Kymera Therapeutics)
Atlas Venture co-founded this company and has backed it for 8+ years. Just raised $602M post-IPO in Dec 2025.

2️⃣ RLAY (Relay Therapeutics)
Third Rock Ventures CREATED this company in 2016 and stayed through IPO. D.E. Shaw Research as co-founder.

3️⃣ TEM (Tempus AI)
Founded by Eric Lefkofsky (Groupon co-founder) after his wife's cancer diagnosis. He owns 27% — that's conviction.

4️⃣ Seaport Therapeutics (Pre-IPO — WATCH THIS)
The same team that sold Karuna to Bristol Myers Squibb for $14 BILLION is doing it again. ALL their original VCs re-invested.

💡 KEY INSIGHT:
"When VCs invest in post-IPO offerings, it means they STILL trust the company — even without insider information advantage."

Stop guessing. Start thinking like a VC.

⚠️ This is not financial advice. Biotech is high-risk. Always do your own research.

#Biotech #VentureCapital #KYMR #RLAY #TEM #BiotechStocks #SmartMoney #WallStreet #StockPicks #InvestingTips #HealthcareStocks #DrugDiscovery #PrecisionMedicine #IPO #Shorts